Skip to main content
. 2016 May 20;6:26273. doi: 10.1038/srep26273

Figure 2. Differential sensitivity to PARP inhibition among colon cancer cell lines is not associated with BRCA1 mutation or loss of BRCA1 expression.

Figure 2

(a) Fold change in BARD1β among select colon cancer cell lines were compared using SYBR green real-time PCR and reported as a percentage of the expression level of PARPi sensitive colon cancer cell line, Caco-2. Quantitative PCR was performed at least three times from three different RNA extractions for each cell line. (*p < 0.05 and **p < 0.01) (b) Real-time PCR on polysomal fractions of Caco-2 colon cancer cells showed amplification of various SVs of BARD1. (c) Untreated and 10 μM PARPi treated Caco-2 and SW480 cells for 4 days were stained with both 4′,6-diamidino-2-phenylindole (DAPI) nuclear fluorescent stain and phospho-histone γH2AX DSB marker. Scale bar represents 5 μm. (d) Nuclear phospho-histone γH2AX foci formation in Fig. 3c were quantified (*p < 0.05 and **p < 0.01). (e) Untreated Caco-2 and SW480 cells were stained with DAPI and anti-RAD51 antibody. 10 μM PARPi treated Caco-2 and SW480 cells for 4 days were stained with DAPI and anti-RAD51 antibody. (f) Nuclear RAD51 foci formation in Fig. 2e were quantified (*p < 0.05 and **p < 0.01).